Taran Therapeutics Presents Promising Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia and Secondary Acute Myeloid Leukemia Treatment
– Of 34 CMML treatment-naïve participants enrolled and treated with lenzilumab plus azacitidine, 22 have

